ORLANDO, Fla. — In June, Dr. Samit Hirawat was appointed chief medical officer of Bristol-Myers Squibb, where he is in charge of the pharma’s late-stage drug development across all therapeutics areas. He joined Bristol after spending 12 years at Novartis. Hirawat’s new job got a lot bigger and more involved last month when Bristol’s merger with Celgene was completed.

STAT interviewed Hirawat here at the annual meeting of the American Society of Hematology, where he talked about Bristol’s commitment to developing CAR-T therapies, how he’s managing the integration of the two pipelines, and whether he’s prepared to say no when data go bad. This interview has been condensed and lightly edited.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy